Bayer Debt to Equity Ratio 2012-2025 | BAYRY
Current and historical debt to equity ratio values for Bayer (BAYRY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bayer debt/equity for the three months ending December 31, 2025 was 1.22.
| Bayer Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-12-31 | $88.79B | $29.49B | 3.01 |
| 2025-09-30 | $87.09B | $34.72B | 2.51 |
| 2025-06-30 | $84.84B | $34.62B | 2.45 |
| 2025-03-31 | $80.70B | $34.33B | 2.35 |
| 2024-12-31 | $85.28B | $34.68B | 2.46 |
| 2024-09-30 | $83.85B | $33.75B | 2.48 |
| 2024-06-30 | $90.47B | $38.60B | 2.34 |
| 2024-03-31 | $91.33B | $38.83B | 2.35 |
| 2023-12-31 | $90.03B | $35.80B | 2.52 |
| 2023-09-30 | $91.09B | $36.51B | 2.50 |
| 2023-06-30 | $92.19B | $40.48B | 2.28 |
| 2023-03-31 | $90.20B | $44.03B | 2.05 |
| 2022-12-31 | $90.56B | $41.01B | 2.21 |
| 2022-09-30 | $90.19B | $41.77B | 2.16 |
| 2022-06-30 | $96.41B | $40.66B | 2.37 |
| 2022-03-31 | $98.95B | $42.20B | 2.35 |
| 2021-12-31 | $103.02B | $39.24B | 2.63 |
| 2021-09-30 | $100.56B | $36.88B | 2.73 |
| 2021-06-30 | $101.03B | $36.84B | 2.74 |
| 2021-03-31 | $101.28B | $41.92B | 2.42 |
| 2020-12-31 | $98.63B | $35.07B | 2.81 |
| 2020-09-30 | $102.92B | $36.80B | 2.80 |
| 2020-06-30 | $96.68B | $39.49B | 2.45 |
| 2020-03-31 | $84.61B | $53.82B | 1.57 |
| 2019-12-31 | $88.19B | $53.22B | 1.66 |
| 2019-09-30 | $94.09B | $51.32B | 1.83 |
| 2019-06-30 | $93.78B | $50.52B | 1.86 |
| 2019-03-31 | $93.27B | $54.61B | 1.71 |
| 2018-12-31 | $94.64B | $54.50B | 1.74 |
| 2018-09-30 | $91.90B | $58.62B | 1.57 |
| 2018-06-30 | $106.51B | $56.31B | 1.89 |
| 2018-03-31 | $45.49B | $47.18B | 0.96 |
| 2017-12-31 | $43.21B | $41.66B | 1.04 |
| 2017-09-30 | $60.82B | $29.13B | 2.09 |
| 2017-06-30 | $51.87B | $39.03B | 1.33 |
| 2017-03-31 | $55.26B | $26.40B | 2.09 |
| 2016-12-31 | $55.71B | $35.30B | 1.58 |
| 2016-09-30 | $57.75B | $27.66B | 2.09 |
| 2016-06-30 | $58.11B | $27.15B | 2.14 |
| 2016-03-31 | $57.21B | $27.33B | 2.09 |
| 2015-12-31 | $53.82B | $28.25B | 1.91 |
| 2015-09-30 | $57.73B | $25.12B | 2.30 |
| 2015-06-30 | $58.85B | $24.80B | 2.37 |
| 2015-03-31 | $61.83B | $24.68B | 2.51 |
| 2014-12-31 | $66.49B | $26.88B | 2.47 |
| 2014-09-30 | $53.51B | $26.92B | 1.99 |
| 2014-06-30 | $48.56B | $26.81B | 1.81 |
| 2014-03-31 | $48.47B | $28.91B | 1.68 |
| 2013-12-31 | $40.53B | $27.63B | 1.47 |
| 2013-09-30 | $42.06B | $26.69B | 1.58 |
| 2013-06-30 | $43.97B | $25.46B | 1.73 |
| 2013-03-31 | $43.71B | $26.13B | 1.67 |
| 2012-12-31 | $42.14B | $23.88B | 1.77 |
| 2012-09-30 | $42.73B | $23.41B | 1.83 |
| 2012-06-30 | $43.42B | $23.84B | 1.82 |
| 2012-03-31 | $44.90B | $26.31B | 1.71 |
| 2011-12-31 | $46.65B | $26.84B | 1.74 |
| 2011-09-30 | $46.60B | $26.91B | 1.73 |
| 2011-06-30 | $46.24B | $27.22B | 1.70 |
| 2011-03-31 | $43.98B | $26.87B | 1.64 |
| 2010-12-31 | $43.30B | $25.09B | 1.73 |
| 2010-09-30 | $43.58B | $23.75B | 1.84 |
| 2010-06-30 | $45.52B | $24.25B | 1.88 |
| 2010-03-31 | $46.91B | $27.19B | 1.73 |
| 2009-12-31 | $44.75B | $26.43B | 1.69 |
| 2009-09-30 | $47.84B | $26.09B | 1.83 |
| 2009-06-30 | $45.20B | $25.21B | 1.79 |
| 2009-03-31 | $49.70B | $22.36B | 2.22 |
| 2008-12-31 | $53.22B | $24.04B | 2.21 |
| 2008-09-30 | $51.76B | $27.59B | 1.88 |
| 2008-06-30 | $53.19B | $27.22B | 1.95 |
| 2008-03-31 | $51.51B | $26.37B | 1.95 |
| 2007-12-31 | $47.37B | $23.06B | 2.05 |
| 2007-09-30 | $47.66B | $23.37B | 2.04 |
| 2007-06-30 | $50.10B | $21.91B | 2.29 |
| 2007-03-31 | $53.81B | $20.84B | 2.58 |
| 2006-12-31 | $54.07B | $16.14B | 3.35 |
| 2006-09-30 | $55.59B | $16.79B | 3.31 |
| 2006-06-30 | $54.49B | $16.12B | 3.38 |
| 2006-03-31 | $29.25B | $14.56B | 2.01 |
| 2005-12-31 | $31.84B | $13.90B | 2.29 |
| 2005-09-30 | $30.82B | $13.62B | 2.26 |
| 2005-06-30 | $31.78B | $13.36B | 2.38 |
| 2005-03-31 | $32.59B | $13.95B | 2.34 |
| 2004-12-31 | $31.63B | $15.40B | 2.05 |
| 2004-09-30 | $30.02B | $15.33B | 1.96 |
| 2004-06-30 | $29.86B | $15.20B | 1.97 |
| 2004-03-31 | $32.06B | $15.59B | 2.06 |
| 2003-12-31 | $31.78B | $15.38B | 2.07 |
| 2003-09-30 | $28.20B | $16.58B | 1.70 |
| 2003-06-30 | $28.99B | $17.19B | 1.69 |
| 2003-03-31 | $26.65B | $16.14B | 1.65 |
| 2002-12-31 | $27.64B | $16.08B | 1.72 |
| 2002-09-30 | $27.90B | $15.87B | 1.76 |
| 2002-06-30 | $26.71B | $14.39B | 1.86 |
| 2002-03-31 | $18.77B | $14.71B | 1.28 |
| 2001-12-31 | $17.83B | $15.00B | 1.19 |
| 2001-09-30 | $18.75B | $14.53B | 1.29 |
| 2001-06-30 | $19.26B | $15.13B | 1.27 |
| 2001-03-31 | $20.21B | $15.19B | 1.33 |
| 2000-12-31 | $18.98B | $15.08B | 1.26 |
| 2000-09-30 | $17.17B | $14.94B | 1.15 |
| 2000-06-30 | $17.30B | $14.35B | 1.21 |
| 2000-03-31 | $18.23B | $14.91B | 1.22 |
| 1999-12-31 | $16.35B | $15.07B | 1.08 |
| 1998-12-31 | $57.44B | $43.26B | 1.33 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |